MedTrace Logo

Immune Response of an Interchangeable Booster Vaccine Against COVID-19 Among Individuals With Risk Factors for Severity

NCT05289206 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4446

Last updated 2022-05-05

No results posted yet for this study

Summary

Experimental, single-arm study in participants with comorbidities, previously immunized with 2 doses of CoronaVac, who will receive a booster vaccine with 1 dose of the Oxford/AstraZeneca vaccine.

Conditions

  • Comorbidities and Coexisting Conditions
  • Healthy

Interventions

OTHER

Vaccine - ChAdOx1-S/nCoV-19 [recombinant]

ChAdOx1-S/nCoV-19 \[recombinant\] - 0.5 mL single dose, intramuscular in deltoid, with an interval of 180 days (+/- 30 days) from the 2nd dose of the initial vaccination schedule with CoronaVac

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado do Amazonas (FAPEAM)

    collaborator UNKNOWN

  • XP Investimentos

    collaborator UNKNOWN

  • Universidade do Estado do Amazonas (UEA)

    collaborator UNKNOWN

  • Oswaldo Cruz Foundation

    collaborator OTHER

  • Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

    lead OTHER

Principal Investigators

  • Marcus Lacerda, PhD · Fundação de Medicina Tropical Dr. Heitor Vieira Dourado

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-30
Primary Completion
2022-03-31
Completion
2022-05-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05289206 on ClinicalTrials.gov